-- Days : -- HRS : -- MIN : -- SEC
Register Now →

All News

L. Elizabeth Budde, MD, PhD.

L. Elizabeth Budde, MD, PhD, oncologist and associate professor at City of Hope, discusses the use of mosunetuzumab in patients with relapsed/refractory follicular lymphoma (R/R FL) who have received 2 or more prior lines of therapy and addresses potential cost-related implications of the drug compared with CAR T-cell therapy.

red cross

Despite the increase in relapse risk, 2-year survival for patients with graft-versus-host disease (GVHD) who received matched sibling donor (MSD) allogeneic hematopoietic cell transplant (allo-HCT) administered post-transplant cyclophosphamide remained similar compared with patients receiving cyclosporine A with methotrexate prophylactically.